BDBM410361 N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide and N-(5-((4aS,5S)-5-(hydroxymethyl)-1,2,4,4a,5,6-hexahydro-[1,4]oxazino[4,3-a][1,5]naphthyridin-9-yl)-6-methylpyridin-3-yl)-3-(trifluoromethyl)benzamide::US10377770, Example 121

SMILES Cc1ncc(NC(=O)c2cccc(c2)C(F)(F)F)cc1-c1cnc2C[C@H](CO)[C@H]3COCCN3c2c1

InChI Key InChIKey=OMISVPHTIWKHHN-HOYKHHGWSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 410361   

TargetRAF proto-oncogene serine/threonine-protein kinase [Y340E,Y341E](Homo sapiens (Human))
Novartis

US Patent
LigandPNGBDBM410361(N-(5-((4aR,5R)-5-(Hydroxymethyl)-1,2,4,4a,5,6-hexa...)
Affinity DataIC50:  0.00900nMAssay Description:The activity of a compound according to the present invention can be assessed by well-known in vitro & in vivo methods. Raf inhibition data provided ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent